Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors

Author： Kloner Robert A Comstock Gary Levine Laurence A Tiger Steven Stecher Vera J

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.15, 2011-10, pp. : 2297-2313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ADMET considerations for phosphodiesterase-5 inhibitors

By Rezvanfar Mohammad Amin Rahimi Hamid Reza Abdollahi Mohammad

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1231-1245

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular Effects of Phosphodiesterase 5 Inhibitors

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3485-3494

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 inhibitors and erectile dysfunction

By Sandner Peter Svenstrup Niels Tinel Hanna Haning Helmut Bischoff Erwin

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 1, 2008-01 ,pp. : 21-33

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase-5 Inhibitors: Future Perspectives

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3540-3551

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite